[Skin Ulcer Caused by Bevacizumab-A Case Report]

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Bevacizumab (Bmab) is a monoclonal antibody used in cancer chemotherapy.
• Dermatological side effects, including skin ulcers and delayed wound healing, are known risks associated with bevacizumab treatment.

Observation:

• A 69-year-old male patient with advanced colorectal cancer developed a skin ulcer after initiating bevacizumab and XELOX chemotherapy.
• The ulcer initially improved upon discontinuation of bevacizumab and supportive care.
• Upon re-administration of bevacizumab, the skin ulcer recurred, despite concurrent antibiotic treatment for suspected actinomycosis.

Findings:

• This case highlights the potential for bevacizumab-induced skin ulcers to recur with re-exposure to the drug.
• Recurrence was observed even when bevacizumab was reintroduced with antibiotic therapy.
• Data from Japan indicates a pattern of recurrence for bevacizumab-associated skin ulcers.

Implications:

• Clinicians should carefully weigh the risks and benefits before re-administering bevacizumab in patients who have developed skin ulcers.
• Further investigation into the mechanisms underlying bevacizumab-induced skin ulceration and recurrence is warranted.
• Management strategies for bevacizumab-related dermatopathy may need to be refined to prevent recurrence.